Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC)

Inclusion Criteria: * Histologically or cytologically confirmed diagnosis of stage IIIB (and is not a candidate for definitive multimodality therapy) or IV ALK-positive NSCLC. * Patients may have received one prior treatment regimen with crizotinib (all other ALK inhibitors are excluded). * Patients may have received prior chemotherapy, biologic therapy, or other investigational agents. ALK inhibitors other than crizotinib are excluded. * Patient has a World Health Organization (WHO) performance status 0-2. Exclusion Criteria: * Prior treatment with an ALK inhibitor other than crizotinib. * History of carcinomatous meningitis. * Presence or history of a malignant disease other than an ALK-positive advanced tumor that has been diagnosed and/or required therapy within the past 3 years. * Clinically significant, uncontrolled heart disease and/or recent cardiac event (within 6 months) * Patient has history of interstitial lung disease or interstitial pneumonitis, including clinically significant radiation pneumonitis (i.e., affecting activities of daily living or requiring therapeutic intervention). * Patient has other severe, acute, or chronic medical conditions * Patient is currently receiving treatment with warfarin sodium (Coumadin®) or any other coumarin-derivative anticoagulants.